Total amount raised
$1.1 Billions
Latest funding date
2/1/2025
Location
Eikon Therapeutics has successfully raised significant capital through multiple funding rounds, with the latest being a Series D round.
Keep reading to explore the intricacies of Eikon Therapeutics' fundraising journey and the investors backing this innovative biopharmaceutical company.
What Is Eikon Therapeutics?
Eikon Therapeutics, founded in 2019, is a biopharmaceutical company based in Hayward, California. The company focuses on developing innovative technologies for drug discovery, utilizing advanced live-cell resolution microscopy and engineering to identify and create new therapeutic candidates.
The founders of Eikon Therapeutics include Eric Betzig, Luke Lavi, Robert Tjian, and Xavier Darzacq. Their approach integrates biology, engineering, and chemistry to streamline the drug discovery process, aiming to enhance the understanding of biological processes at a cellular level.
With a team of 251-500 employees, Eikon Therapeutics leverages its proprietary platforms to advance clinical programs and expand its pipeline of potential medications. The company’s headquarters are located at 3929 Point Eden Way, Hayward, CA 94545.
How Much Funding Has Eikon Therapeutics Raised?
- Seed Round
- Amount Raised: Not publicly disclosed
- Date: January 2019
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To establish the company and develop initial technologies.
- Series A
- Amount Raised: $148M
- Date: May 2021
- Lead Investors: The Column Group
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To advance the development of their live-cell imaging platform.
- Series B
- Amount Raised: $518M
- Date: January 2022
- Lead Investors: High-profile venture capital investors, Abu Dhabi sovereign wealth fund, Canada Pension Plan Investment Board, and insurance companies
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To progress more quickly toward the mission of inventing innovative medicines and to continue making dramatic progress in the industrialization of their live-cell imaging platform.
- Series C
- Amount Raised: $106M
- Date: June 2023
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand their pipeline of potential medications.
- Series D
- Amount Raised: $350.7M
- Date: February 2025
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further advance clinical programs and proprietary platforms.
Total Amount Raised: $1.1227B. Current Valuation: Not publicly disclosed.
Key Investors
- The Column Group
- Details: The Column Group is a venture capital firm that focuses on investing in early-stage life sciences companies. They are known for their deep expertise in biotechnology and pharmaceuticals.
- Investment Focus Areas: Biotechnology, pharmaceuticals, life sciences.
- Notable Investments: NGM Biopharmaceuticals, Nurix Therapeutics, ORIC Pharmaceuticals.
- Abu Dhabi Sovereign Wealth Fund
- Details: The Abu Dhabi Sovereign Wealth Fund is a state-owned investment fund that manages the surplus revenues of the Emirate of Abu Dhabi. It invests globally across various asset classes.
- Investment Focus Areas: Technology, real estate, infrastructure.
- Notable Investments: GlobalFoundries, Reliance Industries, SoftBank Vision Fund.
- Canada Pension Plan Investment Board
- Details: The Canada Pension Plan Investment Board (CPPIB) is a professional investment management organization that invests the funds of the Canada Pension Plan. It aims to ensure sustainable returns for Canadian retirees.
- Investment Focus Areas: Infrastructure, real estate, technology.
- Notable Investments: Ant Financial, Enbridge, Glencore.
- AME Cloud Ventures
- Details: AME Cloud Ventures is a venture capital firm that invests in seed to later-stage companies. It was founded by Yahoo co-founder Jerry Yang.
- Investment Focus Areas: Data, cloud computing, artificial intelligence.
- Notable Investments: Cloudera, DataRobot, Rigetti Computing.
- Insurance Companies
- Details: These are large insurance firms that invest in various sectors to diversify their portfolios. They typically seek steady returns and risk management.
- Investment Focus Areas: Technology, healthcare, diversified portfolios.
- Notable Investments: Not publicly disclosed.
What's Next for Eikon Therapeutics?
With its cutting-edge super-resolution microscopy, Eikon Therapeutics stands poised to revolutionize drug discovery. The company's ability to track individual proteins in live cells opens up vast opportunities for developing treatments for previously undruggable targets. This technological edge positions Eikon to make significant strides in the pharmaceutical industry.
Future fundraising seems promising, given the substantial backing from high-profile investors in previous rounds. As Eikon continues to innovate, it is likely to attract further investment to support its ambitious goals. However, the company must navigate the complexities of integrating advanced technologies and stay ahead in a rapidly evolving field.
Use Clay to Get Funding Data
Sales professionals, take your strategy to the next level by leveraging Clay’s platform to access comprehensive fundraising data on companies like Eikon Therapeutics and gather other critical business insights.
Sign up for free on Clay and start making data-driven decisions today.
